Single domain antibodies targeting CD1d
The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
1. A method for the treatment of cancer comprising administration of a compound to a human patient, wherein said compound comprises a single-domain antibody which binds to human CD1d and is capable of inducing activation of CD1d-restricted T cells, where the single-domain antibody comprises complementarity determining regions CDR1, CDR2 and CDR3, wherein CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 33, CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 54 and CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 75.
2. The method according to claim 1 , wherein the compound is capable of activating invariant natural killer T cells.
3. The method according to claim 1 , wherein the compound is capable of stimulating glycolipid induced activation of invariant natural killer T cells.
4. The method according to claim 1 , wherein the compound is capable of stimulating alpha-galactosyl ceramide induced activation of invariant natural killer T cells.
5. The method according to claim 1 , wherein the compound comprises the amino acid sequence set forth in SEQ ID NO: 12.
6. The method according to claim 1 , wherein the compound comprises further single domain antibodies.
7. The method according to claim 1 , wherein the compound is a bispecific or multispecific compound.
8. The method according to claim 1 , wherein the compound is linked to another antibody.